Artículo

Argentine Guidelines for Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men aged 50 and older

Brance, María Lorena Icon; Larroudé, María S. ; Zamora, Natalia V. ; Bagur, Alicia ; Graf, César E. ; Giacoia, Evangelina ; Diehl, María ; Somma, Luis F. ; Schneeberger, Emilce ; Salerni, Helena H. ; Rey, Paula ; Varsavsky, Mariela ; González, Diana C. ; Massari, Fabio ; Sánchez, Julio A. ; Galich, Ana M. ; Berbotto, Guillermo ; García, María L. ; Zanchetta, María Belén ; Martínez Muñoz, Alejandro ; Chavero, Ignacio ; Ramírez Stieben, Luis Agustín ; Maher, María C. ; Abdala, Rubén ; Pérez, Betiana ; De La Vega, María C. ; Mansur, José L. ; Brun, Lucas Ricardo Martín Icon

Otros responsables

Fecha

08/2023

Editorial

Lippincott Williams

Revista

Jcr - Journal Of Clinical Rheumatology

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1076-1608

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Objective: The aim of this study was to provide an evidence-based framework to guide health care professionals treating patients under glucocorticoid (GC) therapy and develop guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO) in postmenopausal women and men aged ≥50 years. Methods: An expert panel on bone diseases designed a series of clinically meaningful questions following the PICO (Population, Intervention, Comparator, and Outcome) structure. Using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology, we made a systematic literature review, extracted and summarized the effect estimates, and graded the quality of the evidence. The expert panel voted each PICO question and made recommendations after reaching an agreement of at least 70%. Results: Seventeen recommendations (9 strong and 8 conditional) and 8 general principles were developed for postmenopausal women and men aged ≥50 years under GC treatment. Bone mineral density (BMD), occurrence of fragility fractures, probability of fracture at 10 years by Fracture Risk Assessment Tool, and other screening factors for low BMD are recommended for patient evaluation and stratification according to fragility fracture risk. The treatment of patients under GC therapy should include counseling on lifestyle habits and strict control of comorbidities. The goal of GIO treatment is the nonoccurrence of new fragility fractures as well as to increase or maintain BMD in certain clinical situations. This was considered for the therapeutic approach in different clinical scenarios. Conclusions: This GIO guideline provides evidence-based guidance for health care providers treating patients.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa